We only have this paper's title and publication details.
Read it at the sourceCohort analysis reveals how precision treatment improves outcomes in patients with HR+/HER2- breast cancer, suggesting more personalized therapy approaches.
Real-world cohort of patients with advanced HR+/HER2- breast cancer from FUSCC
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: